Despite considerable progress in genome- and proteome-based high-throughput screening methods and in rational drug design, the increase in approved drugs in the past decade did not match the increase of drug development costs. The network approach not only gives a systems-level understanding of drug action and disease complexity, but can also help to improve the efficiency of drug design. Here we give a comprehensive assessment of the analytical tools of network topology and dynamics. We summarize the current knowledge and the state-of-the-art use of chemical similarity, protein structure, protein-protein interaction, signaling, genetic interaction and metabolic networks in the discovery of drug targets . We show how network techniques can help in the identification of single-target, edgetic, multi-target and allo-network drug target candidates. We review the recent boom in network methods helping hit identification, lead selection optimizing drug efficacy, as well as minimizing side-effects and drug toxicity. Successful network-based drug development strategies are shown through the examples of infections, cancer, metabolic diseases, neurodegenerative diseases and aging. Finally, summarizing more than 1100 cited references we suggest an optimized protocol of network-aided drug development, and provide a list of systems-level hallmarks of drug quality. Finally, we highlight network-related drug development trends both at protein structure and cellular levels helping to achieve these hallmarks by a cohesive, global approach.
Despite considerable progress in genome- and proteome-based high-throughput screening methods and in rational drug design, the increase in approved drugs in the past decade did not match the increase of drug development costs. Network description and analysis not only gives a systems-level understanding of drug action and disease complexity, but can also help to improve the efficiency of drug design. We give a comprehensive assessment of the analytical tools of network topology and dynamics. The state-of-the-art use of chemical similarity, protein structure, protein-protein interaction, signaling, genetic interaction and metabolic networks in the discovery of drug targets is summarized. We propose that network targeting follows two basic strategies. The central hit strategy selectively targets central node/edges of the flexible networks of infectious agents or cancer cells to kill them. The network influence strategy works against other diseases, where an efficient reconfiguration of rigid networks needs to be achieved. It is shown how network techniques can help in the identification of single-target, edgetic, multi-target and allo-network drug target candidates. We review the recent boom in network methods helping hit identification, lead selection optimizing drug efficacy, as well as minimizing side-effects and drug toxicity. Successful network-based drug development strategies are shown through the examples of infections, cancer, metabolic diseases, neurodegenerative diseases and aging. Summarizing >1200 references we suggest an optimized protocol of network-aided drug development, and provide a list of systems-level hallmarks of drug quality. Finally, we highlight network-related drug development trends helping to achieve these hallmarks by a cohesive, global approach.
R
The network approach
Network description and analysis
R
Here we
We
R
We summarize the current knowledge and the
The
R
. We show
is summarized. We propose that network targeting follows two basic strategies. The central hit strategy selectively targets central node/edges of the flexible networks of infectious agents or cancer cells to kill them. The network influence strategy works against other diseases, where an efficient reconfiguration of rigid networks needs to be achieved. It is shown
R
Finally, summarizing more than 1100 cited
Summarizing >1200
D
both at protein structure and cellular levels